Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BCG Live · Tice Bcg, BCG

Vaccine (Live attenuated vaccine) · Immune activation, directed at Mycobacterium bovis · developed by Merck Teknika LLC

Approved FDA, Jun 1989

MRK Developer

4 Registered trials

What is BCG Live?

BCG Live (Tice Bcg) is a vaccine containing an attenuated strain of Mycobacterium bovis with immunotherapeutic activity. It activates a Th1 cytokine response including interferon induction. Administered intravesically, it is used to treat non-muscle invasive bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Tice Bcg, BCG, Bacillus Calmette-Guérin (BCG)
Drug type: Vaccine (Live attenuated vaccine)
Targets: Mycobacterium bovis (antigen)
Mechanism: Immune activation, directed at Mycobacterium bovis
Pathways: Th1 cytokine response, interferon induction
Therapy area: Oncology
Developer: Merck Teknika LLC (MRK)
Also in trials of: IBRX
FDA status: Approved as Tice Bcg (June 21, 1989), BLA102821

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07551544	Phase 3	NMIBC	Withdrawn	IBRX
NCT06833073	Phase 2	Urinary Bladder Neoplasms	Recruiting	MRK
NCT03317158	Phase 1/2	Urothelial Carcinoma	Active not recruiting	IBRX
NCT02138734	Phase 1/2	Non-muscle Invasive Bladder Cancer	Active not recruiting	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder CancerCarcinoma in SituNon-muscle Invasive Bladder CancerNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsUrothelial CarcinomaNMIBC

More from Merck Teknika LLC

Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3 Favezelimab Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind BCG Live

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z